ClinicalTrials.gg
RecruitingNCT06860594Updated Oct 21, 2026

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

A Phase 1 interventional study of Biospecimen Collection and Computed Tomography in Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant and Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant, sponsored by National Cancer Institute (NCI). Recruiting at 43 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.

Primary conditionGlioblastomaRegistry: AstrocytomaReclassifiedWhy we changed it
Registry
Astrocytoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glioblastoma
Why
  1. The study's listed conditions name Glioblastoma, a narrower term within Astrocytoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by National Cancer Institute (NCI) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Oct 21, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 122 studies in Glioblastoma by National Cancer Institute (NCI) — 6 open to participants now, 15 under way, 1 of them phase 3. Glioblastoma · National Cancer Institute (NCI).

Planned enrollment
78th of 106
30 · median 48
Started
2025
with 1 other
Phase 1
43 of 122
3 open now
Primary completion
2027-06
later than 8 of 13 live
Registered
121st of 122
by date

Among the 122 studies in Glioblastoma by National Cancer Institute (NCI), this one is the 78th largest by planned enrollment of the 106 interventional ones that give a count, is one of 2 that started in 2025, is one of 43 in phase 1, reaches primary completion later than 8 of the 13 other live ones, and was the 121st registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

6 of the 122 studies in Glioblastoma by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Glioblastoma by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving triapine in combination with radiation therapy may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma or astrocytoma.

Read the detailed description

PRIMARY OBJECTIVE:

I. To identify the safety and maximally tolerated dose (MTD) of oral triapine used in combination with radiation therapy for patients with recurrent glioblastoma (GBM) or astrocytoma.

SECONDARY OBJECTIVES:

I. To observe and record anti-tumor activity. II. To determine the pharmacokinetics of oral triapine in plasma and the central nervous system (CNS).

III. To evaluate the efficacy of triapine when administered in combination with radiation therapy by assessing:

IIIa. Progression-free survival (PFS); IIIb. Overall survival (OS); IIIc. The proportion of patients requiring bevacizumab for symptom control; IIId. The correlation of genetic mutations in select genes (e.g., p53, p16, KRAS, and Pi3k/mTOR/AKT) with tumor response and clinical outcomes.

OUTLINE: This is a dose-escalation study of triapine in combination with radiation therapy.

Patients undergo intensity-modulated radiation therapy (IMRT) once daily (QD) 5 days per week (Monday-Friday) for a total of 10 treatment days over 2 weeks and receive triapine orally (PO) 2 hours prior to IMRT on each radiation treatment day in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) and/or magnetic resonance imaging (MRI) throughout the study as well as blood sample collection during screening and on study. Patients may undergo cerebrospinal fluid (CSF) sample collection during screening.

After completion of study treatment, patients are followed up at 2 weeks after radiation therapy, then every 3 months for up to 5 years from study treatment initiation.

03

Conditions studied

  • Astrocytoma, IDH-Mutant, Grade 2
  • Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant
  • Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant
  • Recurrent Astrocytoma, IDH-Mutant
  • Recurrent Astrocytoma, IDH-Mutant, Grade 3
  • Recurrent Astrocytoma, IDH-Mutant, Grade 4
  • Recurrent Glioblastoma, IDH-Wildtype

Browse trials for

04

In context

Glioblastoma Reclassified

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

This study's planned enrollment of 30 is below the median of 36 across 1,758 interventional studies indexed under Glioblastoma.

Browse Glioblastoma studies →

Lead sponsor

National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 335 are open to participants now.

Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.

Compared within Glioblastoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Astrocytoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have histologically, molecularly, or confirmed recurrent astrocytic tumors including:

    • GBM or variants, IDH-wildtype, grade 2-4 (standard curative measures available or not)
    • Astrocytoma, IDH-mutant, grade 2-4 (standard curative measures available or not)
    • Diffuse midline gliomas, including pediatric-type H3 G34 or E3 K27 mutant tumors.
  • Tumors ≤ 6 cm in maximal diameter.

    • Patients who had recent resection for recurrent tumor must have .
  • Patients must have at least a 6-month break from last dose of radiation therapy.

Re-irradiation within 6 months may increase risk for radiation necrosis/edema, which will affect toxicity assessment and patient safety. Additionally, GBM and other high-grade astrocytic tumors can exhibit pseudo-progression within 6 months from completing definitive, radiation therapy, and re-irradiation during this period will increase risk for misattribution of effect.

  • Prior history of standard dose radiation for gliomas of 59.4-60 gray (Gy) in 1.8-2 Gy per fraction (or equivalent or lower) is allowed.
  • Patients who received non-standard radiation dose regimen (e.g., 40 Gy, 34-35 Gy, 25 Gy) or stereotactic radiosurgery are eligible as long as there is at least one of the following:

    • A new tumor outside the original radiotherapy field as determined by the investigator.
    • There is histologic confirmation of tumor on or resection.
    • Imaging findings are consistent with true progressive disease (on standard MRI sequences, MRI spectroscopy/perfusion, or nuclear medicine imaging).
  • Age ≥ 18 years. Because no dosing or adverse event data are currently available on the use of triapine in patients \< 18 years of age, children are excluded from this study.
  • (ECOG) performance status ≤ 2 ( ≥ 60%).
  • ≥ 1,500/mcL.
  • ≥ 8 g/dL.
  • ≥ 100,000/mcL.
  • Total ≤ 1.5 x institutional (ULN).
  • (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 3 x institutional ULN.
  • Creatinine ≤ 1.5 x ULN OR (GFR) ≥ 50 mL/min/1.73 m\^2.
  • (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • For patients with evidence of chronic virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  • Patients with a history of virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial.
  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the Functional Classification. To be eligible for this trial, patients should be class II or better.
  • Patients must be able to swallow whole capsules.
  • Patients must be able to undergo MRIs with contrast. Patients with non-compatible devices with MRI can be eligible if CT scans of sufficient quality are obtained. However, patients without non-compatible devices may not use CT scans to meet this requirement.
  • The effects of triapine on the developing human fetus are unknown. For this reason and because ribonucleotide reductase (RNR) inhibitor agent and radiation are known to be teratogenic, women of and men must agree to use adequate (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 12 months after finishing study treatment. People of child-bearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 2 weeks of registration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 12 months after completion of triapine administration.
  • Ability to understand and the willingness to sign a written document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion criteria

Exclusion Criteria:

  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia.
  • Patients who are receiving any other agents.
  • Patients who are actively taking medications that are known to induce methemoglobinemia (e.g. sulfonamides, nitrofurans, anti-malarials [primaquine, chloroquine], cyclophosphamide, and ifosfamide).
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine.
  • Patients with known G6PD deficiency. Testing for G6PD deficiency is not required.
  • Patients with uncontrolled intercurrent illness, active infections, or any other significant condition(s) that would make participation in this protocol unreasonably hazardous.
  • Pregnant women are excluded from this study because triapine is a RNR inhibitor agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with triapine, breastfeeding should be discontinued if the mother is treated with triapine. These potential risks may also apply to the radiation used in this study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Treatment (IMRT, triapine)

    Patients undergo IMRT QD 5 days per week (Monday-Friday) for a total of 10 treatment days over 2 weeks and receive triapine PO 2 hours prior to IMRT on each radiation treatment day in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI throughout the study as well as blood sample collection during screening and on study. Patients may undergo CSF sample collection during screening.

    Procedure: Biospecimen Collection · Procedure: Computed Tomography · Radiation: Intensity-Modulated Radiation Therapy · Procedure: Magnetic Resonance Imaging · Drug: Triapine

Interventions

  • ProcedureBiospecimen Collection

    Undergo blood and CSF sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Sample Collection, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, Diagnostic CAT Scan, Diagnostic CAT Scan Service Type, tomography

  • RadiationIntensity-Modulated Radiation Therapy

    Undergo IMRT

    Also known as: IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • Given PO

    Also known as: 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, 3-AP, 3-Apct, OCX-0191, OCX-191, OCX191, PAN-811

07

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicity

    Will be graded in severity according to the Common Terminology Criteria for Adverse Events version 5.0. Frequency and severity of adverse events and tolerability of the regimen will be collected and summarized with descriptive statistics. The maximum grade for each type of toxicity will be recorded for each patient and frequency tables will be reviewed to determine toxicity patterns. Will employ the Backfill Bayesian Optimal Interval design to guide dose escalation and establish the maximal tolerated dose (MTD). The target toxicity rate for the MTD is = 0.25.

    Time frame: Up to 28 days

Secondary outcomes

  1. Response rate

    Response rate will be categorized based on the Response Assessment in Neuro-Oncology criteria, in which tumor response is based on clinical history, physical exam, and imaging findings. The total number of patients in each response category divided by the total number of evaluable patients determines response rate. An evaluable patient is defined as an eligible patient who received at least one dose of triapine. The response rates will be calculated with corresponding 95% exact Clopper-Pearson confidence intervals.

    Time frame: Up to 5 years

  2. Plasma pharmacokinetic (PK) parameters

    Triapine in plasma and peri-tumoral dialysate will be quantified using a validated liquid chromatography-tandem mass spectrometry assay. Plasma PK parameters will be derived and compared to historical controls. Dialysate concentrations will be calculated at multiple time points. Exploratorily, exposure-response relationships will be evaluated.

    Time frame: Up to 2 weeks

  3. Progression-free survival

    Will be estimated using Kaplan Meier curves.

    Time frame: From study enrollment to date of either disease progression or death, assessed up to 5 years

  4. Overall survival

    Will be estimated using Kaplan Meier curves.

    Time frame: From study enrollment to date of death, assessed up to 5 years

  5. Proportion of patients who initiated bevacizumab for symptom control

    Will be calculated using descriptive statistics.

    Time frame: Up to 5 years

  6. Tumor tissue biomarkers

    The presence of genetic alterations, expression of RRM2, and other molecular gene expression signatures will be descriptive in relation to tumor response and clinical outcomes.

    Time frame: Up to 5 years

08

Study locations

36 of 43 sites recruiting
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
    Recruiting
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
    Irvine, California 92612, United States
    Recruiting
    • Site Public Contact · Contactucstudy@uci.edu · 877-827-8839
    • Jerica M. Lomax · Principal investigator
  • UC San Diego Moores Cancer Center
    La Jolla, California 92093, United States
    Recruiting
    • Site Public Contact · Contactcancercto@ucsd.edu · 858-822-5354
    • David E. Piccioni · Principal investigator
  • UC Irvine Health/Chao Family Comprehensive Cancer Center
    Orange, California 92868, United States
    Recruiting
    • Site Public Contact · Contactucstudy@uci.edu · 877-827-8839
    • Jerica M. Lomax · Principal investigator
  • University of California Davis Comprehensive Cancer Center
    Sacramento, California 95817, United States
    Recruiting
    • Site Public Contact · Contact916-734-3089
    • Orwa Aboud · Principal investigator
  • Yale University
    New Haven, Connecticut 06520, United States
    Recruiting
    • Site Public Contact · Contactcanceranswers@yale.edu · 203-785-5702
    • Nicholas A. Blondin · Principal investigator
  • Smilow Cancer Hospital Care Center-Trumbull
    Trumbull, Connecticut 06611, United States
    Recruiting
    • Site Public Contact · Contactcanceranswers@yale.edu · 203-785-5702
    • Nicholas A. Blondin · Principal investigator
  • MedStar Georgetown University Hospital
    Washington D.C., District of Columbia 20007, United States
    Suspended

    Not enrolling at this site — choose another above.

  • UM Sylvester Comprehensive Cancer Center at Coral Gables
    Coral Gables, Florida 33146, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Macarena I. De La Fuente · Principal investigator
  • UM Sylvester Comprehensive Cancer Center at Coral Springs
    Coral Springs, Florida 33065, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Macarena I. De La Fuente · Principal investigator
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach
    Deerfield Beach, Florida 33442, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Macarena I. De La Fuente · Principal investigator
  • UM Sylvester Comprehensive Cancer Center at Doral
    Doral, Florida 33166, United States
    Recruiting
  • UM Sylvester Comprehensive Cancer Center at Hollywood
    Hollywood, Florida 33021, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Macarena I. De La Fuente · Principal investigator
  • University of Miami Miller School of Medicine-Sylvester Cancer Center
    Miami, Florida 33136, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Macarena I. De La Fuente · Principal investigator
  • UM Sylvester Comprehensive Cancer Center at Kendall
    Miami, Florida 33176, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Macarena I. De La Fuente · Principal investigator
  • University of Miami Sylvester Comprehensive Cancer Center at Sole Mia
    North Miami, Florida 33181, United States
    Recruiting
  • UM Sylvester Comprehensive Cancer Center at Plantation
    Plantation, Florida 33324, United States
    Recruiting
    • Site Public Contact · Contact305-243-2647
    • Macarena I. De La Fuente · Principal investigator
  • Emory University Hospital/Winship Cancer Institute
    Atlanta, Georgia 30322, United States
    Recruiting
    • Site Public Contact · Contact404-778-1868
    • Kimberly Hoang · Principal investigator
  • Northwestern University
    Chicago, Illinois 60611, United States
    Recruiting
  • University of Chicago Comprehensive Cancer Center
    Chicago, Illinois 60637, United States
    Recruiting
  • Memorial Hospital East
    Shiloh, Illinois 62269, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • University of Kansas Clinical Research Center
    Fairway, Kansas 66205, United States
    Recruiting
  • University of Kansas Cancer Center
    Kansas City, Kansas 66160, United States
    Recruiting
  • University of Kansas Hospital-Westwood Cancer Center
    Westwood, Kansas 66205, United States
    Recruiting
  • University of Kentucky/Markey Cancer Center
    Lexington, Kentucky 40536, United States
    Recruiting
    • Site Public Contact · Contact859-257-3379
    • John L. Villano · Principal investigator
  • Siteman Cancer Center at Saint Peters Hospital
    City of Saint Peters, Missouri 63376, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Siteman Cancer Center at West County Hospital
    Creve Coeur, Missouri 63141, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Siteman Cancer Center-South County
    St Louis, Missouri 63129, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Siteman Cancer Center at Christian Hospital
    St Louis, Missouri 63136, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • NYU Langone Hospital - Long Island
    Mineola, New York 11501, United States
    Recruiting
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone
    New York, New York 10016, United States
    Recruiting
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
    New York, New York 10032, United States
    Recruiting
  • Carolinas Medical Center/Levine Cancer Institute
    Charlotte, North Carolina 28203, United States
    Recruiting
    • Site Public Contact · Contact800-804-9376
    • Ashley L. Sumrall · Principal investigator
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
    Recruiting
    • Site Public Contact · Contact336-713-6771
    • Roy E. Strowd · Principal investigator
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
    Recruiting
    • Site Public Contact · ContactJamesline@osumc.edu · 800-293-5066
    • Hamid R. Mohtashami · Principal investigator
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
    Recruiting
    • Site Public Contact · Contact412-647-8073
    • Megan Mantica · Principal investigator
  • Vanderbilt University/Ingram Cancer Center
    Nashville, Tennessee 37232, United States
    Recruiting
    • Site Public Contact · Contact800-811-8480
    • Alexander C. Mohler · Principal investigator
  • Huntsman Cancer Institute/University of Utah
    Salt Lake City, Utah 84112, United States
    Recruiting
  • VCU Massey Comprehensive Cancer Center
    Richmond, Virginia 23298, United States
    Recruiting
    • Site Public Contact · ContactCTOclinops@vcu.edu · 804-628-6430
    • Timothy J. Harris · Principal investigator
  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
    Madison, Wisconsin 53718, United States
    Recruiting
  • University of Wisconsin Carbone Cancer Center - University Hospital
    Madison, Wisconsin 53792, United States
    Recruiting
09

References and documents

Individual participant data

Plan to share: Yes — NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Data sharing details ↗ · grants.nih.gov

No publications or documents are linked to this record.

10

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2027, 23 months after the start.

Of 239 non-industry phase 1 interventional studies under Glioblastoma, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 23 months is below that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2025
First posted
Mar 6, 2025
StartActual
Jul 30, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
VCU Massey Comprehensive Cancer Center is now Recruiting
across 3 updates, Oct 13, 2026 – Oct 21, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • VCU Massey Comprehensive Cancer Center · Richmond, United StatesContact added C•••@vcu.edu · •••6430Contact added (no phone or email listed)
  • City of Hope Comprehensive Cancer Center · Duarte, United StatesContact added b•••@coh.org · •••4673Contact added (no phone or email listed)
across 3 updates, Oct 13, 2026 – Oct 21, 2026
Show all 3 updates
  1. Oct 21, 2026
    City of Hope Comprehensive Cancer Center is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • City of Hope Comprehensive Cancer Center · Duarte, United StatesContact added b•••@coh.org · •••4673Contact added (no phone or email listed)
  2. Oct 20, 2026
    City of Hope Comprehensive Cancer Center is now Suspended
    Site contacts Changed at 1 site. See the sites
    Show the site
    • City of Hope Comprehensive Cancer Center · Duarte, United StatesContact removed b•••@coh.org · •••4673Contact removed (no phone or email listed)
  3. Oct 13, 2026
    VCU Massey Comprehensive Cancer Center is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • VCU Massey Comprehensive Cancer Center · Richmond, United StatesContact added C•••@vcu.edu · •••6430Contact added (no phone or email listed)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06860594
Responsible party
Sponsor
First posted
Mar 6, 2025
Start date
Jul 30, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Stephanie M Yoon
principal investigator · City of Hope Comprehensive Cancer Center LAO

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triapine

Start the discussion